These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27346339)

  • 61. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer.
    Jadvar H; Desai B; Ji L; Conti PS; Dorff TB; Groshen SG; Gross ME; Pinski JK; Quinn DI
    Clin Nucl Med; 2012 Jul; 37(7):637-43. PubMed ID: 22691503
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
    Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
    Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of PET-CT with
    Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete biochemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up.
    Winter A; Henke RP; Wawroschek F
    BMC Urol; 2015 Feb; 15(1):10. PubMed ID: 25881245
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Usefulness of
    López Rodríguez E; Tirado Hospital JL; Álvarez Pérez RM; Gómez Izquierdo L; Jiménez-Hoyuela JM
    Actas Urol Esp (Engl Ed); 2020; 44(6):437-443. PubMed ID: 32576406
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 70. FDG PET/CT imaging in prostate adenocarcinoma presenting as isolated brain metastases of unknown origin.
    Erhamamcı S; Reyhan M; Alkan O
    Rev Esp Med Nucl Imagen Mol; 2015; 34(2):146-7. PubMed ID: 25052407
    [No Abstract]   [Full Text] [Related]  

  • 71. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
    Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
    Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lung Metastasis From Prostate Cancer Revealed by 18F-FDG PET/CT Without Osseous Metastasis on Bone Scan.
    Su HY; Chen ML; Hsieh PJ; Hsieh TS; Chao IM
    Clin Nucl Med; 2016 May; 41(5):392-3. PubMed ID: 26859201
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.
    Okotie OT; Aronson WJ; Wieder JA; Liao Y; Dorey F; DeKERNION JB; Freedland SJ
    J Urol; 2004 Jun; 171(6 Pt 1):2260-4. PubMed ID: 15126798
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
    Esch LH; Fahlbusch M; Albers P; Hautzel H; Müller-Mattheis V
    BJU Int; 2017 Sep; 120(3):337-342. PubMed ID: 27860163
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.
    Reske SN; Blumstein NM; Glatting G
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):9-17. PubMed ID: 17828534
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Needle track recurrence after transrectal prostate biopsy detected by ¹⁸F-Choline PET-CT.
    Garcia-Bennett J; Henríquez I; Zugazaga Cortazar A; Fuertes J
    Rev Esp Med Nucl Imagen Mol; 2015; 34(2):128-9. PubMed ID: 25037682
    [No Abstract]   [Full Text] [Related]  

  • 77. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse?
    Greco C; Cascini GL; Tamburrini O
    Prostate Cancer Prostatic Dis; 2008; 11(2):121-8. PubMed ID: 18180806
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    Kanoun S; Walker P; Vrigneaud JM; Depardon E; Barbier V; Humbert O; Moulin M; Créhange G; Cormier L; Loffroy R; Brunotte F; Cochet A
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):986-994. PubMed ID: 28333020
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques?
    Schiavina R; Ceci F; Borghesi M; Brunocilla E; Vagnoni V; Gacci M; Castellucci P; Nanni C; Martorana G; Fanti S
    Curr Radiopharm; 2013 Jun; 6(2):92-5. PubMed ID: 23597246
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.
    Elgamal AA; Troychak MJ; Murphy GP
    Prostate; 1998 Dec; 37(4):261-9. PubMed ID: 9831223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.